质子治疗用于非小细胞肺癌缺氧靶向剂量递增的潜力研究
本研究基于10例IIb-IIIb期非小细胞肺癌患者的HX4-PET影像与氧增强比(OER)放射生物学模型,模拟质子治疗对肿瘤缺氧区域的个体化剂量递增,并与光子VMAT比较。结果显示忽略缺氧可高估TCP达10%,个体化递增最高22%处方剂量可恢复至名义TCP的0.9%以内,同时质子治疗仍降低心、肺、食管和脊髓平均剂量及NTCP。
要点
- 忽略肿瘤缺氧可高估TCP达10%,个体化剂量递增至多22%处方剂量可恢复至名义TCP的0.9%以内。
- 质子治疗剂量递增同时降低心脏、肺、食管和脊髓平均剂量,并降低放射性肺炎、心脏毒性和食管炎NTCP。
- 质子治疗可在不增加正常组织并发症概率的情况下,缓解缺氧所致放射抵抗对肿瘤控制的影响。
核心结论
- 质子治疗对NSCLC患者个体化缺氧区域剂量递增可缓解缺氧所致放射抵抗对TCP的降低,同时降低NTCP。
研究设计与样本
- 基于10例IIb-IIIb期NSCLC患者的HX4-PET影像与OER放射生物学模型,模拟质子治疗对原发靶区最缺氧区域的剂量递增,并与光子VMAT比较。
主要发现
- 忽略肿瘤缺氧区域可导致TCP高估达10%,个体化剂量递增最高达处方剂量的22%可使TCP平均恢复至名义值0.9%以内。
- 质子治疗剂量递增相比非递增VMAT方案,心脏平均剂量降低14.3 GyRBE,肺降低8.3 GyRBE,食管降低6.9 GyRBE,脊髓降低3.8 Gy。
- 上述剂量降低预测使放射性肺炎NTCP降低11.3%,高级别心脏毒性NTCP降低7.4%,食管炎NTCP降低7.5%。
关键数值与推荐
- 剂量递增幅度最高为处方剂量的22%,TCP恢复至名义值平均差异在0.9%以内。
- 质子治疗相比非递增VMAT:心脏平均剂量-14.3 GyRBE,肺-8.3 GyRBE,食管-6.9 GyRBE,脊髓-3.8 Gy。
- NTCP预测降低:放射性肺炎-11.3%,高级别心脏毒性-7.4%,食管炎-7.5%。
临床怎么用
- 对NSCLC缺氧区域可考虑质子治疗个体化剂量递增,以改善局部区域肿瘤控制并降低正常组织并发症概率。
- HX4-PET联合OER放射生物学模型可用于指导患者特异性缺氧靶向剂量递增计划设计。
局限性
- 研究基于10例患者的模拟计划,非临床治疗结果,需前瞻性临床验证。
- 剂量递增效果依赖PET缺氧影像与OER模型的准确性,未报告其他潜在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypoxia is known to be prevalent in solid tumors such as non-small cell lung cancer (NSCLC) and reportedly correlates with poor prognostic clinical outcome. PET imaging can provide in-vivo hypoxia measurements to support targeted radiotherapy treatment planning. We explore the potential of proton therapy in performing patient-specific dose escalation and compare it with photon volumetric modulated arc therapy (VMAT). METHODS: Dose escalation has been calibrated to the patient specific tumor response of ten stage IIb-IIIb NSCLC patients by combining HX4-PET imaging and radiobiological modelling of oxygen enhancement ratio (OER) to target variable tumor hypoxia. In a dose-escalation-by-contour approach, escalated dose levels were simulated to the most hypoxic region of the primary target and its effectiveness in improving loco-regional tumor control was assessed. Furthermore, the impact on normal tissue of proton treatments including dose escalation was evaluated in comparison to the normal tissue complication probability (NTCP) of conventional VMAT plans. RESULTS: Ignoring regions of tumor hypoxia can cause overestimation of TCP values by up to 10%, which can effectively be recovered on average to within 0.9% of the nominal TCP, using patient-specific dose escalations of up to 22% of the prescribed dose to PET defined hypoxic regions. Despite such dose escalations, the use of protons could also simultaneously reduce mean doses to the heart (- 14.3 GyRBE), lung (- 8.3 GyRBE), esophagus (- 6.9 GyRBE) and spinal cord (- 3.8 Gy) compared to non-escalated VMAT plans. These reductions are predicted to lead to clinically relevant decreases in NTCP for radiation-induced pneumonitis (- 11.3%), high grade heart toxicity (- 7.4%) and esophagitis (- 7.5%). CONCLUSIONS: This study suggests that the administration of proton therapy for dose escalation to patient specific regions of tumor hypoxia in the treatment of NSCLC can mitigate TCP reduction due to hypoxia-induced radio resistance, while simultaneously reducing NTCP levels even when compared to non-escalated treatments delivered with state-of-the-art photon techniques.
引用
- Köthe A, Bizzocchi N, Safai S, et al. Investigating the potential of proton therapy for hypoxia-targeted dose escalation in non-small cell lung cancer. Radiat Oncol. 2021. PMID: 34635135. doi:10.1186/s13014-021-01914-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。